Purchase Order 36C25623P0943
Award Date 5/5/23
Potential Completion Date 10/5/23
Potential Value $52K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Cambridge, MA 02139, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm fixed price purchase order contract awarded by the Department of Veterans Affairs (VA) to Vericel Corporation, a for-profit manufacturer of advanced cell therapy products. The $52,252 contract is for the delivery of surgical implants, with a period of performance ending on November 22, 2023. Vericel Corporation is a registered federal contractor that has secured over 50 contracts with the VA and the Defense Health Agency since 2015, primarily to provide specialized medical...
- This $56,171 firm fixed price purchase order was awarded by the U.S. Department of Veterans Affairs' Veterans Integrated Service Network 21 to Vericel Corporation, a for-profit manufacturer of advanced cell therapy products. The contract is for the supply of MACI (matrix-induced autologous chondrocyte implantation) cultured chondrocyte implants, surgical implants, membranes, and other related products to support orthopedic and reconstructive healthcare services for veterans. Vericel...
- This is a $111,154.00 firm fixed price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration Veterans Integrated Service Network 6 to Vericel Corporation, a for-profit manufacturer of medical products. The contract is for the delivery of MACI implants, which are cultured chondrocyte implants used for cartilage repair procedures. Vericel Corporation has been awarded over 50 similar federal contracts from 2015-2023 to provide surgical implants,...
- This federal contract award, valued at $56,171.00, was issued by the Veterans Integrated Service Network 12 (VISN 12), which is part of the U.S. Department of Veterans Affairs (VA). The contract was awarded to Vericel Corporation, a for-profit manufacturer of advanced cell therapy products, primarily for the supply of the company's MACI cultured chondrocyte implant and other surgical implants, membranes, and biological products. The contract is a firm fixed price purchase order with a completion...
- This federal contract award to Vericel Corporation, a for-profit medical technology company, is for the supply of MACI (matrix-induced autologous chondrocyte implantation) cultured chondrocyte implants, surgical implants, membranes, and other biological products used in cartilage repair and orthopedic procedures. The contract, valued at $60,665.00, is a firm fixed-price purchase order awarded by the U.S. Department of Veterans Affairs (VA), specifically through Veterans Integrated Service...
- This federal contract award is for the supply of a surgical implant (tissue) by Vericel Corporation, a for-profit manufacturer of advanced cell therapy products, to the Department of Veterans Affairs (VA). The $52,252.00 firm fixed price purchase order is not set aside and has a completion date of June 26, 2023. Vericel, which has been a registered federal contractor since 2015, has secured over 50 contracts with the VA's Veterans Health Administration, primarily to provide specialized medical...
- This is a firm fixed price purchase order contract awarded by the Department of Veterans Affairs (VA) Veterans Health Administration to Vericel Corporation, a for-profit manufacturer of medical products including advanced cell therapies and surgical implants. The contract, valued at $56,171.00, is for the delivery of Vericel's MACI cultured chondrocyte knee implant, PROSE surgical implants, assembled membranes, and cartilage grafts and matrices to VA medical facilities. The contract has a...
- This federal contract award was issued by the Defense Health Agency to Vericel Corporation, a medical technology company based in Cambridge, Massachusetts. The $47,204.00 firm fixed-price purchase order is for the delivery of MACI (matrix-induced autologous chondrocyte implantation) cultured chondrocyte implants, surgical implants, membranes, and biological products used in cartilage repair procedures. The award does not have a set-aside designation, indicating Vericel competed on the open...
- This federal contract award, valued at $56,171.00, was made by the U.S. Department of Veterans Affairs (VA) to Vericel Corporation, a for-profit manufacturer of advanced cell therapy products. The contract is for the provision of IMPLANT, a surgical implant product, with an ultimate completion date of August 16, 2024. This contract was not set aside for a specific business type. Vericel Corporation, a long-standing federal contractor since 2015, has secured numerous contracts with the VA and the...
- This is a firm fixed price purchase order contract awarded by the Department of Veterans Affairs (VA) to Vericel Corporation, a manufacturer of advanced cell therapy products. The contract, valued at $56,171.00, is for the delivery of CARTILAGE supplies, specifically MACI implants, surgical implants, assembled membranes, cartilage grafts, and matrices. These specialized medical products are used to support orthopedic and reconstructive procedures for veterans and active military personnel. The...
This $52,252 firm fixed price purchase order was awarded by the Department of Veterans Affairs (VA) to Vericel Corporation, a for-profit manufacturer of advanced cell therapy products. The contract is for the supply of MACI, a cultured chondrocyte implant used for cartilage repair procedures, as well as other surgical implants, membranes, and biological products to support healthcare services for veterans and military personnel. Vericel has secured numerous federal contracts with the VA and Defense Health Agency, demonstrating its significant role in providing cutting-edge cell therapy and tissue engineering solutions for orthopedic and reconstructive procedures. The contract does not have a set-aside designation.
Generated 9/7/24, 11:49 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $52.3k | 5/5/23 |